TrialThe Lancet. Oncology2024

Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.

Mariano Provencio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.